Pyxis Oncology (PYXS) EBT Margin (2024 - 2025)
Pyxis Oncology's (PYXS) quarterly EBT Margin came in at 154.04% in Q4 2025, up 75.96% on a QoQ basis from 640.82% in Q2 2025.
Pyxis Oncology (PYXS) EBT Margin (2024 - 2025) Analysis & Trends
Pyxis Oncology (PYXS) has 2 years of EBT Margin data on file, last reported at 154.04% in Q4 2025.
- On a quarterly basis, EBT Margin changed N/A year-over-year to 154.04% in Q4 2025; TTM through Dec 2025 was 574.64%, a 2980.0% decrease from a year earlier, with the FY2025 full-year figure at 564.55%, down 7220.0% from the prior year.
- EBT Margin for Q4 2025 stood at 154.04%, up from 640.82% in the prior quarter.
- Over the last five years, EBT Margin for PYXS reached as high as 72.66% in Q1 2024 and fell as low as 640.82% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 17.13% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 41.95% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.05% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 34.77% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Pyxis Oncology | 166.54 Mn | 99.69 Mn | 8.65 Mn | -154.04% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -154.04% |
| Jun 30, 2025 | -640.82% |
| Mar 31, 2024 | -72.66% |